Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
ID: 353912Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353912

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-005.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB) through a cooperative agreement aimed at enhancing clinical trial efficiency for the prevention and early intervention of Type 1 Diabetes (T1D). The HUB will focus on coordinating communication, outreach, and developing innovative tools to improve participant screening and recruitment, with a strong emphasis on including a Plan for Enhancing Diverse Perspectives (PEDP) in all proposals. This initiative is critical for fostering inclusivity and improving clinical trial outcomes, particularly for underrepresented groups in T1D studies. The NIH has allocated $1 million for one award, supporting up to $750,000 in direct costs annually over a maximum five-year project period, with applications due by October 17, 2024. Interested applicants can find more information and guidance at the provided NIH link or contact grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DK-25-005-Full-Announcement.html
    RFA-DK-25-005.html
    The Department of Health and Human Services announces a funding opportunity for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB) through the National Institutes of Health (NIH). This initiative aims to enhance clinical trial efficiency, focusing on the prevention and early intervention of Type 1 Diabetes (T1D). The HUB will coordinate communication, outreach, and the development of innovative tools to increase participant screening and recruitment. A critical component of this funding request is a Plan for Enhancing Diverse Perspectives (PEDP), which applicants must include for their proposals to be considered complete. The funding opportunity allows for new and renewal applications, with NIDDK committing $1 million for one award, supporting up to $750,000 in direct costs annually over a maximum five-year project period. Eligible applicants encompass various organizations, including higher education institutions, non-profits, and government entities, requiring them to register with SAM, Grants.gov, and eRA Commons. The proposed work should articulate strategies for effective recruitment and retention, particularly targeting underrepresented groups in T1D studies. The HUB’s activities will involve close collaboration with the TrialNet Coordinating Center and a robust steering committee while adhering to guidelines that ensure diversity and community engagement. The NOFO emphasizes the need for a multidimensional approach to trial implementation, aiming to foster inclusivity and enhance clinical trial outcomes.
    Similar Opportunities
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK Centers for Diabetes Translation Research (P30 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Centers for Diabetes Translation Research (CDTR) under the funding opportunity RFA-DK-26-001, aimed at advancing diabetes translational research from clinical settings to community practice. This initiative seeks to foster innovative research that addresses health equity and reduces diabetes-related disparities through multidisciplinary collaborations and core services that enhance productivity and synergy among funded investigators. Eligible applicants include a wide range of institutions, such as higher education institutions, nonprofits, and government entities, with annual budgets capped at $400,000, potentially increasing to $500,000 for specific cores. Applications are due by May 12, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Limited Competition Funding Opportunity titled "High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards." This initiative aims to support the development of unique capabilities and resources to address critical gaps in clinical and translational science within awarded UM1 Clinical and Translational Science Awards (CTSA) Program Hubs. The funding opportunity, numbered PAR-25-156, allows for project budgets of up to $500,000 per year over a project period of up to five years, with applications involving clinical trials being optional. Interested applicants, primarily from public and state-controlled institutions of higher education, must submit detailed integration plans, milestones, and sustainability evaluations by the closing date of September 28, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards." This initiative aims to support the development and demonstration of innovative resources and capabilities within Clinical and Translational Science Awards (CTSA) Program hubs, specifically targeting critical gaps and roadblocks in clinical research. Successful applicants, who must be active UM1 CTSA award recipients, will propose projects lasting up to five years with an annual budget cap of $500,000, emphasizing collaboration and innovation in health research. Interested parties should note that the application deadline is September 14, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Clinical and Translational Science Award (UM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the Clinical and Translational Science Award (CTSA) Program, aimed at enhancing clinical and translational research through collaborative partnerships. This initiative invites applications for hubs that will focus on improving the efficiency of clinical translation, addressing health disparities, and fostering innovative research methodologies, with a particular emphasis on community engagement and workforce development. Successful applicants, which may include higher education institutions and nonprofit organizations, are expected to outline strategic management and demonstrate strong leadership, with projects capped at seven years and a submission deadline of September 28, 2027. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the funding opportunity page at https://grants.nih.gov/grants/guide/pa-files/PAR-24-272.html.
    NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Notice of Funding Opportunity (NOFO) for the NIAID Clinical Trial Implementation Cooperative Agreement (U01), aimed at supporting high-risk clinical trials that enhance the understanding of human diseases. This funding opportunity encourages applications for investigator-initiated, milestone-driven clinical trials, with each application permitted to propose only one clinical trial that must demonstrate a hypothesis-driven approach. The initiative emphasizes the importance of mechanistic studies within clinical trials and requires a robust plan for managing trial complexity and participant safety. Interested applicants can find additional details and guidelines at the provided NIH link, with the earliest submission date set for April 12, 2024, and the application deadline on January 13, 2027. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    NCI National Clinical Trials Network - Network Lead Academic Participating Sites (UG1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Cancer Institute (NCI) for the establishment of Network Lead Academic Participating Sites (LAPS) within the National Clinical Trials Network (NCTN) to enhance cancer clinical trials for adult patients. This initiative aims to foster scientific leadership and collaboration among U.S. Network Groups, with a focus on robust trial accrual and outreach to underrepresented populations. The NCI plans to allocate up to $35.1 million to support 32 to 40 awards, with each award having a maximum budget of $1.7 million per year over a six-year project period. Interested applicants can find more information and application guidelines at the provided link, with proposals due by February 24, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small Research Project Grants (R01s) aimed at clinical trials focused on diseases under the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative encourages the submission of pilot and feasibility clinical trials that will provide foundational data for larger, definitive trials intended to improve the prevention and treatment of various health conditions, without the requirement of preliminary efficacy data. The program supports innovative research ideas and emphasizes equitable recruitment from diverse populations, with a maximum grant duration of three years and funding up to $200,000 per year. Interested applicants can find more information and submit their applications by May 7, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.